Institutional shares held 246 Million
15.1M calls
10.9M puts
Total value of holdings $24.9B
$1.53B calls
$1.11B puts
Market Cap $39.7B
391,200,000 Shares Out.
Institutional ownership 62.87%
# of Institutions 1,001


Latest Institutional Activity in MRNA

Top Purchases

Q1 2024
Ark Investment Management LLC Shares Held: 1.22M ($123M)
Q1 2024
Sumitomo Mitsui Trust Holdings, Inc. Shares Held: 1.55M ($157M)
Q1 2024
Quattro Financial Advisors LLC Shares Held: 87.1K ($8.83M)
Q1 2024
Tb Alternative Assets Ltd. Shares Held: 59.9K ($6.07M)
Q1 2024
Douglas Lane & Associates, LLC Shares Held: 393K ($39.9M)

Top Sells

Q1 2024
Allspring Global Investments Holdings, LLC Shares Held: 18.3K ($1.86M)
Q1 2024
Apeiron Capital LTD Shares Held: 7.07K ($717K)
Q1 2024
State Of Alaska, Department Of Revenue Shares Held: 62.5K ($6.34M)
Q1 2024
Richard P Slaughter Associates Inc Shares Held: 24.4K ($2.48M)
Q1 2024
Banque Cantonale Vaudoise Shares Held: 27.9K ($2.83M)

About MRNA

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.


Insider Transactions at MRNA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
887K Shares
From 11 Insiders
Grant, award, or other acquisition 79.4K shares
Other acquisition or disposition 17.9K shares
Exercise of conversion of derivative security 790K shares
Sell / Disposition
1.35M Shares
From 6 Insiders
Open market or private sale 1.35M shares

Related Articles

Track Institutional and Insider Activities on MRNA

Follow Moderna, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MRNA shares.

Notify only if

Insider Trading

Get notified when an Moderna, Inc. insider buys or sells MRNA shares.

Notify only if

News

Receive news related to Moderna, Inc.

Track Activities on MRNA